{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T14:39:46Z","timestamp":1793543986503,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aimed to assess the biodistribution and radiation dosimetry of <jats:sup>68<\/jats:sup>Ga-DATA<jats:sup>5m<\/jats:sup> LM4 in patients with gastroenteropancreatic neuroendocrine tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Eight patients (5 females and 3 males) with various gastroenteropancreatic neuroendocrine tumors were included in the study. Each patient underwent 3 whole-body PET scans at 10, 60, and 120 minutes after receiving an IV injection of approximately 162.5 MBq of <jats:sup>68<\/jats:sup>Ga-DATA<jats:sup>5m<\/jats:sup> LM4. Organs considered for dosimetric analysis included the liver, heart, spleen, kidneys, adrenal glands, and lumbar vertebrae (L2 to L4). Dosimetric calculations were performed using the OLINDA\/EXM 2.2 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Physiological uptake of <jats:sup>68<\/jats:sup>Ga-DATA<jats:sup>5m<\/jats:sup> LM4 was observed in the pituitary gland, spleen, liver, adrenal glands, and the urinary tract (kidneys and urinary bladder) for all patients. The kidneys received the highest absorbed doses at (4.77E-02 \u00b1 1.49E-02 mSv\/MBq). The mean effective dose was 2.61E-03 \u00b1 5.99E-04 mSv\/MBq.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-DATA<jats:sup>5m<\/jats:sup> LM4 injection is safe and is primarily excreted through urine, delivering the highest radiation dose to the kidneys.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005649","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T21:00:40Z","timestamp":1736197240000},"page":"e194-e201","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Biodistribution and Dosimetry Evaluation of the Radiolabeled Somatostatin Receptor Antagonist 68Ga-DATA5m LM4 in Molecular Imaging of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Patients"],"prefix":"10.1097","volume":"50","author":[{"given":"Sanjana","family":"Ballal","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4589-2623","authenticated-orcid":false,"given":"Parvind","family":"Sheokand","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav P.","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Roesch","sequence":"additional","affiliation":[{"name":"Department of Chemistry\u2013TRIGA Site, Johannes Gutenberg University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4984-169X","authenticated-orcid":false,"given":"Rahul","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-6644","authenticated-orcid":false,"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0447-1355","authenticated-orcid":false,"given":"Euy Sung","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Chemistry\u2013TRIGA Site, Johannes Gutenberg University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1386-3721","authenticated-orcid":false,"given":"Prashant","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4792-3083","authenticated-orcid":false,"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"bib1-20250303","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/0972-3919.125760","article-title":"PET\/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: an overview and single institutional experience from India","volume":"29","year":"2014","journal-title":"Indian J Nucl Med"},{"key":"bib2-20250303","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.semnuclmed.2012.01.002","article-title":"Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms","volume":"42","year":"2012","journal-title":"Semin Nucl Med"},{"key":"bib3-20250303","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/thno.3645","article-title":"Theranostics: from molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy\u2014the Bad Berka experience","volume":"2","year":"2012","journal-title":"Theranostics"},{"key":"bib4-20250303","first-page":"113","article-title":"Neuropathology of drug addictions and substance misuse","year":"2016","journal-title":"Neuropathol Drug Addict Subst Misuse"},{"key":"bib5-20250303","first-page":"437","article-title":"Comparison of (111)in-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy","volume":"58","year":"1998","journal-title":"Cancer Res"},{"key":"bib6-20250303","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/ar800188e","article-title":"Tumor imaging and therapy using radiolabeled somatostatin analogues","volume":"42","year":"2009","journal-title":"Acc Chem Res"},{"key":"bib7-20250303","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"bib8-20250303","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin receptor antagonists for imaging and therapy","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib9-20250303","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"bib10-20250303","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.2967\/jnumed.120.253096","article-title":"A prospective, randomized, double-blind study to evaluate the safety, biodistribution, and dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib11-20250303","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.2967\/jnumed.111.095778","article-title":"Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib12-20250303","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","article-title":"Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"key":"bib13-20250303","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/jlcr.3755","article-title":"Design and development of the theranostic pair 177Lu-OPS201\/68Ga-OPS202 for targeting somatostatin receptor expressing tumors","volume":"62","year":"2019","journal-title":"J Label Compd Radiopharm"},{"key":"bib14-20250303","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2967\/jnumed.111.087999","article-title":"PET of somatostatin receptor\u2013positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib15-20250303","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/cmdc.201500092","article-title":"Approaching \u201ckit-type\u201d labelling with (68)Ga: the DATA chelators","volume":"10","year":"2015","journal-title":"ChemMedChem"},{"key":"bib16-20250303","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","article-title":"Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators","volume":"5","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"key":"bib17-20250303","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-019-04611-1","article-title":"Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET\/CT","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib18-20250303","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.1002\/chem.201701508","article-title":"Equilibrium, kinetic and structural properties of gallium(III) and some divalent metal complexes formed with the new DATAm and DATA5m ligands","volume":"23","year":"2017","journal-title":"Chemistry"},{"key":"bib19-20250303","doi-asserted-by":"crossref","first-page":"14590","DOI":"10.3390\/ijms232314590","article-title":"[68Ga]Ga-DATA5m LM4, a PET radiotracer in the diagnosis of SST2R-positive tumors: preclinical and first clinical results","volume":"23","year":"2022","journal-title":"Int J Mol Sci"},{"key":"bib20-20250303","first-page":"776","article-title":"[111In]in\/[177Lu]Lu-AAZTA5-LM4 SST2R-antagonists in cancer theranostics: from preclinical testing to first patient results","volume":"26","year":"2023","journal-title":"Pharmaceutics"},{"key":"bib21-20250303","first-page":"28","article-title":"Impact of antagonist peptides and chelators on the diagnostic performance of PET\/CT using gallium-68-labeled somatostatin receptor antagonists","volume":"6","year":"2022","journal-title":"J Pancreatology"},{"key":"bib22-20250303","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00259-007-0587-y","article-title":"68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors","volume":"35","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib23-20250303","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","article-title":"Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib24-20250303","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","article-title":"First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety, and efficacy","volume":"62","year":"2021","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:00:36Z","timestamp":1741024836000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005649","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}